Presentation

Strategies and Practices of Clinical Supply Management for Multi-Regional Clinical Trials (IN CHINESE)

Biotech studies in China have increasingly become an important part of global drug innovation, and drug developers in China have begun to seek a broader international market for these innovative products. Striving for efficient and flexible implementation of Multi-Regional Clinical Trial (MRCT) operations and supply chain management will be critical for the success of new drugs being developed overseas. Learn about the MRCT trends in studies from China to overseas, as well as how clinical supply strategy considerations in different clinical phases can help in understanding risk assessment when developing a global supply plan. Additionally, discover how trial complexity factors can influence clinical supply strategy and execution practices as well. This presentation reviews the key points of clinical supply management which can ultimately help lead to the success of global studies, especially for sponsors in China and across the Asia-Pacific region. PRESENTATION IS IN CHINESE

Learn more about:

MRCT trends inside and outside of China (including a clinical supply practice case study about QPs)

Clinical supply strategy considerations in different clinical phases

Trial complexity factors influencing clinical supply strategy and execution practices

Business Email Address*

First Name*

Last Name*

Company*

Title*

Business Phone

Country

State or Province

Buying Horizon*

Asset ID

Asset Type

Asset URL

Download Center - Date Stamp

Download Center - Visit Count

ZZ - Last SFDC Campaign ID

Unique ID

Browser

auxCountry

auxState

Why Catalent?

Catalyst + Talent

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 70 billion doses of more than 7,000 products to over 1,000 customers annually. Catalent’s expert workforce exceeds 17,000, including more than 2,500 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated $4 billion in revenue in its 2021 fiscal year. For more information, visit www.catalent.com.

More products. Better treatments. Reliably supplied.™